Patients with a smoking history who have lung adenocarcinoma and a targetable alteration have the same likelihood of benefitting from targeted therapy as patients without a smoking history and a targetable alteration.
A groundbreaking study demonstrated a 38% risk reduction of disease worsening or death for patients receiving an immunotherapy plus chemotherapy combination as initial treatment for advanced non-squamous NSCLC.
Patients with advanced non-small cell lung cancer (NSCLC) who undergo salvage chemotherapy are 30% more likely to achieve partial response if they have been treated with a PD-1/PD-L1 checkpoint inhibitor, according to a presentation at the European Lung Cancer Conference (Geneva, Switzerland; abstract 91PD).
Patients with lung cancer who are treated with immunotherapy may be at increased risk of severe adverse events after receiving the seasonal influenza vaccination, according to results of a study presented at the European Lung Cancer Conference (April 25, 2017; abstract 112P_PR).
None of the patients in a study with lung cancer and hepatic metastases experienced an objective response in their liver tumors after anti-PD1 therapy, according to research presented at ASCO’s Society for Immunotherapy of Cancer’s 2017 Clinical Immuno-Oncology Symposium (February 23-25, 2017; abstract 38).